PT  - JOURNAL ARTICLE
AU  - R R Anis
AU  - K R Karsch
TI  - The future of drug eluting stents
AID  - 10.1136/hrt.2005.068288
DP  - 2006 May 01
TA  - Heart
PG  - 585--588
VI  - 92
IP  - 5
4099  - http://heart.bmj.com/content/92/5/585.short
4100  - http://heart.bmj.com/content/92/5/585.full
SO  - Heart2006 May 01; 92
AB  - In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10–40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in preventing restenosis for the first year after implantation. Recently, new stents have emerged that are loaded with anti-inflammatory, antimigratory, antiproliferative, or pro-healing drugs. These drugs are supposed to inhibit inflammation and neointimal growth and subsequently ISR. The future of DES lies in the development of better stents with new stent designs, better polymers including biological polymers and biological biodissolvable stent coatings, and new, better drugs.